{'52WeekChange': -0.0075758696,
 'SandP52WeekChange': 0.0644362,
 'address1': '8 HaSatat Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 1.31,
 'askSize': 800,
 'averageDailyVolume10Day': 186775,
 'averageVolume': 605331,
 'averageVolume10days': 186775,
 'beta': 0.796638,
 'beta3Year': None,
 'bid': 1.28,
 'bidSize': 800,
 'bookValue': 0.864,
 'category': None,
 'circulatingSupply': None,
 'city': "Modi'in",
 'companyOfficers': [],
 'country': 'Israel',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 1.32,
 'dayLow': 1.2501,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -0.954,
 'enterpriseToRevenue': 27.191,
 'enterpriseValue': 19278584,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '972 8 993 5001',
 'fiftyDayAverage': 1.2698286,
 'fiftyTwoWeekHigh': 1.64,
 'fiftyTwoWeekLow': 0.9,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 20406899,
 'forwardEps': -0.54,
 'forwardPE': -2.4259257,
 'fromCurrency': None,
 'fullTimeEmployees': 38,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.26728,
 'heldPercentInstitutions': 0.22850999,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/vblrx.com',
 'longBusinessSummary': 'Vascular Biogenics Ltd., a clinical-stage '
                        'biopharmaceutical company, focuses on the discovery, '
                        'development, and commercialization of treatments for '
                        "cancer. The company's program is based on its "
                        'proprietary vascular targeting system platform '
                        'technology, which utilizes genetically targeted '
                        'therapy to destroy newly formed or angiogenic blood '
                        'vessels. Its lead product candidate is VB-111, a '
                        'gene-based biologic that is in Phase III clinical '
                        'trials for the treatment of recurrent glioblastoma, '
                        'an aggressive form of brain cancer; and in Phase III '
                        'clinical trials for recurrent platinum-resistant '
                        'ovarian cancer, as well as for Phase II clinical '
                        'trials for iodine-resistant differentiated thyroid '
                        'cancer. The company is also developing VB-111, which '
                        'is in Phase I clinical trials for the treatment of '
                        'patients with various types of advanced metastatic '
                        'cancer types, including thyroid cancer, '
                        'neuroendocrine cancer, renal cell carcinoma, and lung '
                        'cancer. In addition, it is developing VB-511, an '
                        'anti-angiogenic candidate for oncology; VB-211 and '
                        'VB-411, which are pro-angiogenic candidates for the '
                        'treatment of peripheral vascular diseases; VB-201, a '
                        'Lecinoxoid-based compound for the control of chronic '
                        'inflammatory disorders; and VB-600 that is in '
                        'pre-clinical stage for targeting of MOSPD2 for '
                        'immuno-oncology and anti-inflammatory applications. '
                        'The company was formerly known as Medicard Ltd. and '
                        'changed its name to Vascular Biogenics Ltd. in '
                        'January 2003. Vascular Biogenics Ltd. was founded in '
                        "2000 and is headquartered in Modi'in, Israel.",
 'longName': 'Vascular Biogenics Ltd.',
 'market': 'us_market',
 'marketCap': 62744676,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_4211633',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -20628000,
 'nextFiscalYearEnd': 1640908800,
 'open': 1.28,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '972 8 993 5000',
 'previousClose': 1.29,
 'priceHint': 4,
 'priceToBook': 1.5162036,
 'priceToSalesTrailing12Months': 88.49743,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 1.32,
 'regularMarketDayLow': 1.2501,
 'regularMarketOpen': 1.28,
 'regularMarketPreviousClose': 1.29,
 'regularMarketPrice': 1.28,
 'regularMarketVolume': 124220,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 47896700,
 'sharesPercentSharesOut': 0.0063,
 'sharesShort': 302130,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 282972,
 'shortName': 'Vascular Biogenics Ltd.',
 'shortPercentOfFloat': 0.0081,
 'shortRatio': 0.4,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'VBLT',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.574,
 'twoHundredDayAverage': 1.3109713,
 'volume': 124220,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.vblrx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '78106'}